Physiomics collaboration with Merck to last another year
Physiomics
1.50p
16:55 25/04/24
Physiomics announced on Monday that, following a successful collaboration and pursuant to the master services agreement signed with US pharmaceuticals giant Merck in November last year, it had agreed with a programme of work for the next calendar year.
FTSE AIM All-Share
753.12
16:50 25/04/24
Health Care Equipment & Services
11,737.57
17:09 25/04/24
The AIM-traded firm said both itself and Merck had entered into contracts with a total value of £0.44m for projects that were envisaged to be completed during calendar 2019, and which would span a range of drug targets and treatment types in both pre-clinical and clinical settings.
In its 2018 programme of work with Merck, Physiomics said it believed it had developed “genuinely ground-breaking” predictive models that would add significant value to drug development programmes.
The two companies had provisionally agreed that they would aim to publish selected elements of their work at one or more major conferences in 2019.
“We are now entering the eighth year of our relationship with Merck, during which time we have provided a range of pre-clinical and clinical predictive modelling services using our ‘Virtual Tumour’ technology,” said Physiomics chief executive officer Dr Jim Millen.
“We remain immensely proud to be working with one of the world's foremost pharmaceutical companies, in an area as important and rapidly growing as oncology.
“We look forward to this collaboration continuing.”